Recall Register

Food, drugs, devices › Diagnostic Hybrids, Inc.

Device recall: Quidel MicroVue Intact PTH EIA, Model 8044. An enzyme immunoassay for the quantification of Intact Parathyroid Hormone (

FDA enforcement event 79595 · Class III · initiated 26 Oct 2016 · status Terminated · terminated 28 Aug 2020

DeviceVoluntary: Firm initiated1 product recordAthens, OH

Diagnostic Hybrids, Inc. (Athens, OH) initiated this device recall on 26 Oct 2016; FDA lists 1 product record under event 79595, classified Class III.

FDA defines Class III as a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences. 5% of the 1,232 device enforcement events initiated in 2016 carry the same class.

Status: Terminated, terminated 28 Aug 2020. Initiation: voluntary: firm initiated. Diagnostic Hybrids, Inc. has 6 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Diagnostic Hybrids, Inc., Athens, OH.

Reason for recall

"There may be a loss of separation between Calibrators A and B which may impact the assay calibration at the lower end of the assay."

Distribution

"The product was distributed to the following countries: Singapore, Switzerland"

Product records

Recall numberProductQuantityClassStatusReport date
Z-1520-2018Quidel MicroVue Intact PTH EIA, Model 8044. An enzyme immunoassay for the quantification of Intact Parathyroid Hormone (PTH) in serum.26Class IIITerminated2 May 2018

Context

5%of 2016 device events are Class III1,232 events that year
1product record in this eventfirm median: 1
6events on this register for the firm

Other enforcement events for Diagnostic Hybrids, Inc.

InitiatedProduct (first record)TypeClassRecords
4 Apr 2017MicroVue CIC-C1q EIA, Model A001. An enzyme immunoassay for the detection of circulating immune complexes in human serumDeviceClass II1
14 Jul 2016MicroVue BAP EIA, Model 8012, provides a quantitative measure of bone-specific alkaline phosphatase (BAP) activity in seDeviceClass II1
3 Nov 2015MicroVue CIC-C1q EIA, Model A001. The MicroVue CIC-C1q EIA is for detection of circulating immune complexes (CIC) in humDeviceClass III3
16 Oct 2014MicroVue Bb Plus EIA is packaged as a kit which contains all reagent components to perform the test. In vitro diagnosticDeviceClass II1
31 Dec 2012Diagnostic Hybrids, Inc., RhMK, Model #:49-0600, 49-0600A, 49-0102A, and 49-T075A. Culture media, used in the cultivatioDeviceClass III1

All 6 events for Diagnostic Hybrids, Inc.

Questions and answers

Why was this device recalled?

FDA's record gives the reason for recall as: "There may be a loss of separation between Calibrators A and B which may impact the assay calibration at the lower end of the assay."

What does Class III mean?

FDA classifies recalls by relative degree of health hazard. Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.

Where was the product distributed?

FDA's distribution pattern field reads: "The product was distributed to the following countries: Singapore, Switzerland"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 28 Aug 2020. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA device enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.